TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7564895
Drug: Methyl nicotinate
Normalized name: Methyl Nicotinate
DrugBank: Methyl nicotinate (DB13882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyl nicotinate (MN) 5% ethanol solution
Study: 2250114
Drug: Combined heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined heat and radiation therapy (thermoradiotherapy)
Study: 6985998
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of aspirin per day
Study: 8771219
Drug: Combined cognitive-behavioral/psychopharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined cognitive-behavioral/psychopharmacological treatment (nortriptyline or fluoxetine in AN-R, fluoxetine or amineptine in AN-BP)
Study: 8771219
Drug: Fluoxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine treatment in AN-R patients
Study: 8771219
Drug: Fluoxetine or
Normalized name: fluoxetine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine or amineptine treatment in AN-BP patients
Study: 2251437
Drug: Salbutamol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (100 mcg, 2 puffs)
Study: 2251437
Drug: Oxitropium bromide
Normalized name: oxitropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxitropium bromide (100 mcg, 2 puffs)
Study: 2251437
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Salbutamol and Oxitropium bromide
Study: 6109480
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A - BCAA solution with 12 g N (852 mmol) and 41.1% BCAA
Study: 6109480
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B - Control solution with 18 g N (1278 mmol) and 21.1% BCAA
Study: 28114265
Drug: NSAIDs (ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (ketorolac tromethamine 10 mg, 2 tablets daily for 2 days and amoxicillin 500 mg, 3 tablets daily for 7 days) + corticosteroids (betamethasone 2 mL injection within 10 hours after surgery)
Study: 28114265
Drug: NSAIDs (ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (ketorolac tromethamine 10 mg, 2 tablets daily for 2 days and amoxicillin 500 mg, 3 tablets daily for 7 days)
Study: 25894843
Drug: Homotaurine 100
Normalized name: HYPOTAURINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homotaurine 100 mg
Study: 19473833
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus pemetrexed (500 mg/m2 pemetrexed IV followed by 75 mg/m2 cisplatin IV on day 1)
Study: 19473833
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus gemcitabine (1250 mg/m2 on days 1 and 8 and 75 mg/m2 cisplatin on day 1)
Study: 11800185
Drug: Daily brief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily brief preference assessments
Study: 7979291
Drug: Dapsone 200
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone 200 mg weekly
Study: 7979291
Drug: Dapsone 200
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone 200 mg plus pyrimethamine 25 mg weekly
Study: 7979291
Drug: Dapsone 200
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone 200 mg plus pyrimethamine 75 mg weekly
Study: 29194698
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg oral dose with verapamil
Study: 22836861
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral refeeding (RORF)
Study: 18551287
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of T1-weighted images (T1WI), T2-weighted images (T2WI), and fluid-attenuated inversion recovery (FLAIR) images
Study: 18551287
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of T1WI and FLAIR images
Study: 18551287
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of T2WI and FLAIR images
Study: 18551287
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of T1WI and T2WI images
Study: 18551287
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of T1WI, T2WI, and FLAIR images
Study: 14745057
Drug: Lidocaine 5
Normalized name: lidocaine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 5 mg/kg IV during 30 minutes
Study: 14745057
Drug: Mexiletine titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine titrated from 400 to 1,000 mg per day (mean 737 mg/day)
Study: 9852694
Drug: pentazocine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: pentazocine 0.3 mg.kg‐1 followed by thiamylal 5 mg.kg‐1
Study: 9852694
Drug: pentazocine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: pentazocine 0.6 mg.kg‐1 followed by thiamylal 5 mg.kg‐1
Study: 9852694
Drug: thiamylal 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: thiamylal 5 mg.kg‐1
Study: 8208390
Drug: Phentolamine (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine (35 mg)
Study: 2927132
Drug: Ethanol (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.7 g/kg, p.o.)
Study: 27501650
Drug: 30-mL normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-mL normal saline bolus
Study: 22554751
Drug: Etching with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etching with 30% phosphoric acid for 15 seconds with daily brushing
Study: 22554751
Drug: Etching with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etching with 30% phosphoric acid for 30 seconds with daily brushing
Study: 22554751
Drug: Non-etched control
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-etched control with daily brushing
Study: 18852529
Drug: 5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g/d glycine
Study: 18852529
Drug: 5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g/d placebo
Study: 11262783
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (300 U/kg twice a week)
Study: 11262783
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (300 U/kg twice a week) and preoperative autologous blood donation
Study: 11262783
Drug: Autologous blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous blood administration without concurrent erythropoietin
Study: 3377382
Drug: Pilocarpine 4%
Normalized name: PILOCARPINE 4% SOLN,OPH
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine 4% gel
Study: 28432266
Drug: Intra-Arterial Treatment
Normalized name: METHOTREXATE 25 mg in 1 mL INTRA-ARTERIAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-Arterial Treatment (IAT)
Study: 25369890
Drug: Calcifediol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcifediol (20 μg per day)
Study: 25369890
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (20 μg or 800 IU per day)
Study: 23289005
Drug: Percutaneous adhesiolysis
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous adhesiolysis with caudal epidural injections, including 5 mL of 2% preservative-free lidocaine, 6 mL of 10% hypertonic sodium chloride solution, and 6 mg of non-particulate betamethasone.
Study: 11344343
Drug: Salmeterol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol plus low-dose fluticasone (42 microg of salmeterol and 88 microg of FP)
Study: 11344343
Drug: Higher-dose fluticasone
Normalized name: fluticasone Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose fluticasone (220 microg)
Study: 11344343
Drug: Salmeterol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol plus low-dose FP
Study: 7937520
Drug: R(−)ibuprofen (intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: R(−)ibuprofen (intravenously infused as a racemic mixture)
Study: 7937520
Drug: R(−)ibuprofen (intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: R(−)ibuprofen (intravenously infused alone)
Study: 7937520
Drug: S(+)ibuprofen (dosed
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)ibuprofen (dosed as S(+)ibuprofen)
Study: 7937520
Drug: R(−)ibuprofen (concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: R(−)ibuprofen (concurrent administration with S(+)ibuprofen)
Study: 7937520
Drug: R(−)ibuprofen (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: R(−)ibuprofen (intravenous dose)
Study: 7937520
Drug: R(−)ibuprofen lysinate
Normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: R(−)ibuprofen lysinate (oral dose)
Study: 7937520
Drug: S(+)ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: S(+)ibuprofen
Study: 7937520
Drug: R(−)ibuprofen (dosed
Approvals — FDA: no, EMA: no, PMDA: no
Description: R(−)ibuprofen (dosed alone)
Study: 8971313
Drug: Indomethacin 200
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin 200 mg
Study: 1485176
Drug: ondansetron 32
Normalized name: ondansetron 32 MG in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 32 mg IV x 1
Study: 1485176
Drug: ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 8 mg IV x 1
Study: 1485176
Drug: ondansetron 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 0.15 mg/kg IV every 4 hours x 3
Study: 16335904
Drug: Citalopram (8-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (8-week administration)
Study: 19143690
Drug: Tramadol 2
Normalized name: traMADol 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 2 mg.kg(‐1)
Study: 9579457
Drug: Intravenous albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous albuterol
Study: 30965138
Drug: High-dose methotrexate/cytarabine-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate/cytarabine-based induction followed by ASCT
Study: 23587090
Drug: Text message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text message reminder system for oral glucose tolerance test at 6 weeks postpartum, with further reminders at 3 months and 6 months if they do not respond to indicate test completion.
Study: 12878366
Drug: Indapamide SR
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide SR 1.5 mg once daily for 3 months
Study: 10868557
Drug: Combination hydrocodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination hydrocodone 7.5 mg and ibuprofen 200 mg
Study: 10868557
Drug: Combination oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination oxycodone 5 mg and acetaminophen 325 mg
Study: 9200361
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of erythromycin estolate (40 mg/kg/d; maximum dose 1 g/d)
Study: 9200361
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days of erythromycin estolate (40 mg/kg/d; maximum dose 1 g/d)
Study: 1443486
Drug: Subcutaneous infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infiltration with 1% lignocaine
Study: 3026006
Drug: Sulbactam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulbactam (0.5 g) plus ampicillin (1 g)
Study: 31329985
Drug: Physical therapy-related
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy-related tweets
Study: 26488833
Drug: Text messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text messaging intervention (daily texts for adherence and weekly for symptoms for 21-28 days)
Study: 18305998
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment with T4
Study: 12628877
Drug: Oral azithromycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral azithromycin, 500 mg on day 1 and 250 mg per day for days 2 to 5
Study: 12628877
Drug: Oral levofloxacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral levofloxacin, 500 mg q24h for 7 days
Study: 11387366
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy and autologous stem-cell transplantation (ASCT)
Study: 11387366
Drug: Conventional consolidation/maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional consolidation/maintenance chemotherapy (CC)
Study: 3312701
Drug: Oral TA-064
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TA-064 (20 mg)
Study: 3312701
Drug: Intravenous dobutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dobutamine (5 micrograms/kg/min)
Study: 26906023
Drug: Daily use
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use of an antiretroviral tablet (tenofovir or Truvada)
Study: 26906023
Drug: Daily use
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use of tenofovir gel
Study: 21255959
Drug: Substance abuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance abuse treatment (n = 113)
Study: 21255959
Drug: No substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: No substance abuse treatment (n = 127)
Study: 10681321
Drug: DZ-2640 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZ-2640 25 mg
Study: 10681321
Drug: DZ-2640 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZ-2640 400 mg
Study: 10681321
Drug: DZ-2640 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZ-2640 100 mg (fasted state)
Study: 10681321
Drug: DZ-2640 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZ-2640 100 mg (fed state)
Study: 10681321
Drug: DZ-2640 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZ-2640 (all doses)
Study: 9316463
Drug: Orlistat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (200 mg) with a pure fat meal (10% Intralipid)
Study: 9316463
Drug: Orlistat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (200 mg) with a meal containing free fatty acids
Study: 9316463
Drug: Orlistat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (200 mg) with an albumin-glucose meal
Study: 8420767
Drug: Fibrin adhesive
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin adhesive (0.8‐1.4 ml) injected after fine needle puncture
Study: 20435858
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (HS) inhalation for 4 weeks, twice daily
Study: 20435858
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (IS) inhalation for 4 weeks, twice daily
Study: 18388031
Drug: cilostazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilostazol (200 mg/d)
Study: 18388031
Drug: pentoxifylline (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: pentoxifylline (1200 mg/d)
Study: 12108312
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose regimen of quinine (20 mg salt/kg initial loading dose, followed by 10 mg salt/kg maintenance dose)
Study: 12108312
Drug: Regimen without
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen without loading dose (15 mg salt/kg)
Study: 12108312
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose regimen of quinine
Study: 12108312
Drug: Regimen without
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen without loading dose
Study: 7814759
Drug: Two permucosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two permucosal cylindric implants
Study: 11573634
Drug: bupivacaine 2.5
Normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 2.5 mg plus fentanyl 25 microg (group F)
Study: 11573634
Drug: bupivacaine 2.5
Normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 2.5 mg plus diamorphine 250 microg (group D)
Study: 28664420
Drug: Positive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive treatment beliefs
Study: 28664420
Drug: Negative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative treatment beliefs
Study: 24641883
Drug: 1.6 g/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g/kg/d protein (2×‐RDA)
Study: 24641883
Drug: 2.4 g/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g/kg/d protein (3×‐RDA)
Study: 24641883
Drug: 0.8 g/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg/d protein (RDA)
Study: 22254072
Drug: Total calcium
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total calcium intake with supplements
Study: 15986266
Drug: Comprehensive intravenous
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive intravenous and oral hydration
Study: 12560310
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (70 mg x kg(‐1) at induction followed by 30 mg x kg(‐1) x hr(‐1))
Study: 10329891
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy (betamethasone 12 mg IM, repeated after 24 hours)
Study: 2007038
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: Injection of 8 ml mixture of 2% lidocaine hydrochloride jelly and saline at a dilution of 1:3
Study: 2007038
Drug: Group D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D: Injection of 8 ml mixture of 2% lidocaine hydrochloride jelly and saline at a dilution of 1:1
Study: 31064808
Drug: Meningococcal B
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal B (4CMenB) vaccine
Study: 30371895
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate 1000-mg + prednisone 5-mg + ADT (AAP group)
Study: 26245497
Drug: 3-day dexamethasone
Normalized name: dexamethasone 3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day dexamethasone (8 mg IV on day 1, followed by oral dexamethasone on days 2 and 3)
Study: 26245497
Drug: Single-dose dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose dexamethasone (8 mg IV on day 1)
Study: 22659656
Drug: Probucol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (500 mg/d) plus levamlodipine besylate (2.5 mg/d) plus benazepril (10 mg/d)
Study: 22659656
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (levamlodipine besylate 2.5 mg/d plus benazepril 10 mg/d)
Study: 19070356
Drug: Combination inhaled
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination inhaled corticosteroid with a long-acting beta-agonist
Study: 17187165
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg nightly for one year
Study: 17187165
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 or 100 mg as needed for 12 months
Study: 9771058
Drug: Reflexology treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reflexology treatment (14 sessions over four months)
Study: 2655436
Drug: Acarbose 300
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose 300 mg
Study: 2655436
Drug: Lactulose 30
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose 30 g
Study: 369673
Drug: Self-recording and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-recording and monthly home visits
Study: 369673
Drug: Monthly home
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly home visits only
Study: 369673
Drug: Neither self-recording
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither self-recording nor monthly home visits
Study: 28399611
Drug: Blue-water infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue-water infusion colonoscopy (BWIC)
Study: 21177516
Drug: Self-Administered Computer-Aided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-Administered Computer-Aided Exposure (CAE-SA)
Study: 19761717
Drug: Dihydroartemisinin (DHA)
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Artenimol (DB11638)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Dihydroartemisinin (DHA) 300 mg daily for 2 days
Study: 19761717
Drug: Artesunate 300
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate 300 mg daily for 2 days
Study: 17514186
Drug: Donepezil (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (titrated to 10 mg daily)
Study: 15496603
Drug: Cow milk
Normalized name: cow milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow milk formula with 72 mg/L supplemental ribonucleotides (FN)